Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-05-07

Role of retinoid and estrogen receptors in cell cycle control and apoptosis in breast cancer cells - identification of targets

Obiettivo



Research objectives and content Nuclear receptor ligands (e.g. steroid and thyroid hormone, vitamin D and retinoid agonists and antagonists) are known to modulate cell proliferation, differentiation and apoptosis both in vivo and in vitro. Endocrine therapies in breast and prostate cancer are routinely used in the clinic, and retinoid treatment has largely improved the prognosis of acute promyelocytic leukemia.Moreover a variety of other cancers show promise for treatment with nuclear receptor ligands. Yet, despite the medical and pharmaceutical importance of the nuclear receptor family, and despite rapidly accumulating knowledge about the key players regulating cell cycling and those promoting or inhibiting cell death, next to nothing is known about the regulatory circuits by which nuclear receptors govern the activities of these 'master' genes. Our aim is to decipher these mechanisms by studying nuclear receptor action at multiple functional levels in breast cancer cells (ER+ and ER- cells), a model system in which proliferation,differentiation and apoptosis are regulated by exposure to estrogens, antiestrogens and retinoids. To achieve this goal we will pursue the following studies: a) define the effects of estrogen and retinoids on expression /activity of known key regulators of cell proliferation and cell death, b) identify and characterize, using differential cloning and display technologies, novel factors implicated in these processes c) investigate how estrogens,antiestrogens and retinoic acid alone or in combination affect the expression of these targets, and d) identify synthetic retinoids which can inhibit breast cancer cells proliferation or induce breast cancer cell death. Training content (objective, benefit and expected impact) The completion of this project will provide an important insight into the mechanistic basis of nuclear receptor-mediated cell cycle regulation and apoptosis, increasing our comprehension of both receptor action and the regulatory circuitries governing cell cycle progression and apoptosis, and pave the way towards novel strategies for therapeutics intervention in cancer. Links with industry / industrial relevance (22) The IGBMC has several links established with European Pharmaceutical companies, such as chering AG Berlin, and Roussel-Uclaf, Paris. Dr Gronemeyer is coordinator of an ongoing BIOMED project (BMH4 CT96-0181) to which both companies contribute, and has completed a BIOTECH project (BIO2-CT93 ()473) to which also the applicants'lab (group leader: Dr. Aranda) contributed, thus creating the original contacts resulting in the present application. Due to the intensive links of the IGBMC, in particular the Gronemeyer laboratory, with the pharmacological sector, any results obtained in the course of the proposed study can be optimally exploited.

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: Il Vocabolario Scientifico Europeo.

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Programma(i)

Programmi di finanziamento pluriennali che definiscono le priorità dell’UE in materia di ricerca e innovazione.

Argomento(i)

Gli inviti a presentare proposte sono suddivisi per argomenti. Un argomento definisce un’area o un tema specifico per il quale i candidati possono presentare proposte. La descrizione di un argomento comprende il suo ambito specifico e l’impatto previsto del progetto finanziato.

Invito a presentare proposte

Procedura per invitare i candidati a presentare proposte di progetti, con l’obiettivo di ricevere finanziamenti dall’UE.

Dati non disponibili

Meccanismo di finanziamento

Meccanismo di finanziamento (o «Tipo di azione») all’interno di un programma con caratteristiche comuni. Specifica: l’ambito di ciò che viene finanziato; il tasso di rimborso; i criteri di valutazione specifici per qualificarsi per il finanziamento; l’uso di forme semplificate di costi come gli importi forfettari.

RGI - Research grants (individual fellowships)

Coordinatore

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Contributo UE
Nessun dato
Indirizzo
Rue Laurent Fries 1
67404 ILLKIRCH GRAFFENSTADEN
Francia

Mostra sulla mappa

Costo totale

I costi totali sostenuti dall’organizzazione per partecipare al progetto, compresi i costi diretti e indiretti. Questo importo è un sottoinsieme del bilancio complessivo del progetto.

Nessun dato
Il mio fascicolo 0 0